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Parkinson\'s disease (PD) is the second most common neurodegenerative disease after Alzheimer\'s disease, affecting approximately 2%‐3% of the global population aged ≥65 years.[^1^](#cns13436-bib-0001){ref-type="ref"} The loss of dopaminergic (DA) neurons in the substantia nigral pars compacta (SNc) and intracellular α‐synuclein deposition are known as PD's pivotal pathological characteristics. Although its etiology remains to be fully elucidated, the hypothesis that environmental and genetic factors play essential roles in the initiation and progression of PD is acknowledged worldwide.[^2^](#cns13436-bib-0002){ref-type="ref"} Over the past two decades, substantial progress has been made in our understanding of the genetic basis of parkinsonism through the identification of 19 monogenic disease‐causing genes. In addition, emerging evidence suggests that some monogenic genes can also increase the risk of sporadic PD through different mechanisms.[^3^](#cns13436-bib-0003){ref-type="ref"}

Previous studies have demonstrated that mitochondrial dysfunction plays a fundamental role in the pathogenesis of PD.[^4^](#cns13436-bib-0004){ref-type="ref"} Moreover, mitochondrial homeostasis has been related to mutations of *Parkin*, *Pink1*, and *DJ‐1*.[^5^](#cns13436-bib-0005){ref-type="ref"} Ubiquinol‐cytochrome c reductase core protein I (UQCRC1) is a component of the complex III in the respiratory chain complex. Recently, Lin et al used a whole‐exome sequencing and discovered a novel candidate pathogenetic missense variant (c.941A \> C p.Y314S) of the *UQCRC1* gene in a Taiwanese family with autosomal dominant parkinsonism.[^6^](#cns13436-bib-0006){ref-type="ref"} To further investigate the association between *UQCRC1* and PD in eastern China, we performed a *UQCRC1* genetic analysis in a cohort of sporadic PD patients and healthy controls.

We recruited 452 Chinese Han patients with sporadic PD and 450 sex‐, age‐, and ethnicity‐matched healthy controls from the Second Affiliated Hospital of Zhejiang University (Hangzhou, China) between October 2016 and January 2019. All study participants were diagnosed according to the Movement Disorder Society clinical diagnostic criteria for PD.[^7^](#cns13436-bib-0007){ref-type="ref"} The basic information and demographic characteristics of participants are all shown in Data [S1](#cns13436-sup-0001){ref-type="supplementary-material"}. All participants provided written informed consent. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Zhejiang University of Medicine.

Blood samples were obtained from all participants. Genomic DNA was then extracted from peripheral blood leukocytes using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s protocol. The exon and intron‐exon boundaries of the *UQCRC1* gene were amplified by polymerase chain reaction. Detailed information on primers and annealing temperature is shown in Data [S2](#cns13436-sup-0002){ref-type="supplementary-material"}. DNA products were directly sequenced using a Genetic Analyzer (ABI 3730XL) and analyzed with Chromas software and Mutation Surveyor software (SoftGenetics).

PD cases and healthy controls were matched for age and sex using a nonparametric test (Shapiro‐Wilk normality test, *P* \< .05) and Pearson\'s *χ* ^2^ test, respectively. We also used Pearson\'s *χ* ^2^ test, *χ* ^2^ with Yates correction test or Fisher exact test to compare the allele frequencies in PD patients and healthy controls. The Hardy‐Weinberg principle was used to ascertain the normal distribution of genotype frequencies in PD patients and healthy controls. Statistical analysis was performed using SPSS20.0 software (SPSS Inc). A two‐tailed *P* \< .05 was considered as threshold for statistical significance. The pathogenicity of missense variants was predicted using in silico tools including PolyPhen2, SIFT, CADD, as recommended by the American College of Medical Genetics and Genomics.[^8^](#cns13436-bib-0008){ref-type="ref"}

In this study, we enrolled 452 sporadic PD cases and 450 healthy controls. There were no significant differences in age and sex distribution between patients and controls (Data [S1](#cns13436-sup-0001){ref-type="supplementary-material"}). We identified three synonymous variants (p.V388=, p.A108=, and p.S473=) and four nonsynonymous variants (p.D215H, p.S4A, p.P267R, and p.N308S) of the *UQCRC1* gene. The p.A108 = and p.S4A variants were detected exclusively in PD patients (Table [1](#cns13436-tbl-0001){ref-type="table"}). Moreover, the homozygous p.V388 = variant and the p.P267R variant were identified separately in two PD patients. However, we did not detect the previously reported p.Y314S variant (Lin et al, 2019). Analysis using publicly available resources indicated all four nonsynonymous variants should not be deleterious (Table [2](#cns13436-tbl-0002){ref-type="table"}). Furthermore, the frequencies of the seven variants showed no statistically significant differences between PD patients and controls. Representative images of the variants are presented in Data [S3](#cns13436-sup-0003){ref-type="supplementary-material"}.

###### 

Variants identified in UQCRC1 in our study

  Chromosomal position   Accession number   Variant      Number of carrying variants   PD vs controls                              
  ---------------------- ------------------ ------------ ----------------------------- ---------------- ---- --------------------- -------
  Chr3:48637964          rs140583334        c.1164G\>T   p.V388=                       42               40   1.050 (0.667‐1.654)   0.833
  Chr3:48642187          NA                 c.324C\>T    p.A108=                       1                0    NA                    1.000
  Chr3:48636585          rs182453765        c.1419C\>T   p.S473=                       12               14   0.849 (0.388‐1.857)   0.682
  Chr3:48641060          rs17080284         c.643G\>C    p.D215H                       29               31   0.927 (0.549‐1.565)   0.776
  Chr3:48647044          NA                 c.10T \> G   p.S4A                         1                0    NA                    1.000
  Chr3:48638807          rs149245457        c.800C\>G    p.P267R                       22               15   1.484 (0.759‐2.899)   0.245
  Chr3:48638451          rs187641562        c.923A\>G    p.N308S                       2                3    0.662 (0.110‐3.982)   0.996

Abbreviations: CI, confidence interval; NA, not available; OR, odds ratio; *P*, *P*‐value; PD, Parkinson\'s disease.

John Wiley & Sons, Ltd

###### 

Allele frequencies and pathogenicity prediction of identified UQCRC1 missense variants

  Missense variants   Freq.gnom AD(East Asian)   Freq.ExAC (East Asian)   Freq.1000G (East Asian)   SIFT score   Polyphen2 score   CADD
  ------------------- -------------------------- ------------------------ ------------------------- ------------ ----------------- -------
  p.D215H             0.0291                     0.0327                   0.0238                    0.097        0.997             25.4
  p.S4A               NA                         NA                       NA                        0.274        0.175             12.69
  p.P267R             0.0410                     0.0360                   0.0526                    0.051        0.052             9
  p.N308S             0.0034                     0.0042                   0.002                     0.258        0.093             15.41

Threshold values for deleteriousness: SIFT \<0.05; polyphen2 \>0.86; CADD \>15.

Abbreviation: NA, not available.

John Wiley & Sons, Ltd

The *UQCRC1* gene encodes ubiquinol‐cytochrome c reductase core protein I, which is a subunit of complex III of the respiratory chain. As one of eleven subunits of complex III, UQCRC1 is a nuclear‐encoded protein localized in the inner mitochondrial membrane. Previous studies of *UQCRC1* have focused mainly on its roles in various tumors, such as malignant pleural mesothelioma and pancreatic ductal adenocarcinoma, suggesting that *UQCRC1* may contribute to carcinogenesis.[^9^](#cns13436-bib-0009){ref-type="ref"}, [^10^](#cns13436-bib-0010){ref-type="ref"} Notably, mitochondrial dysfunction also plays a crucial role in the pathogenesis of PD.[^4^](#cns13436-bib-0004){ref-type="ref"}, [^11^](#cns13436-bib-0011){ref-type="ref"} Therefore, it can be hypothesized that *UQCRC1* variants may play a role in the development of PD. Recently, *UQCRC1* was identified as a candidate pathogenic gene for PD.[^6^](#cns13436-bib-0006){ref-type="ref"} Nevertheless, we did not find an association between sporadic PD and *UQCRC1* in our study. Our data do not support that *UQCRC1* mutation is a common genetic factor for sporadic patients in eastern China, but our study cannot rule out its pathogenic role in PD due to the limited ethnic background and sample size. Furthermore, in consideration of the role of outer mitochondrial membrane signaling in Parkinson\'s disease, proteins residing in or translocating to the outer mitochondrial membrane following mitochondrial activities deserve closer attention and be important in genetic analyses for PD.[^12^](#cns13436-bib-0012){ref-type="ref"}

In conclusion, our study indicates that *UQCRC1* may not be involved in pathogenesis of PD in eastern China. Further genetic analysis with larger sample sizes from diverse ethnic populations and functional assays are still needed to clarify the role of *UQCRC1* in the pathogenesis of PD.

CONFLICT OF INTEREST {#cns13436-sec-0003}
--------------------

The authors declare no conflicts of interest.

FUNDING INFORMATION {#cns13436-sec-0004}
-------------------

This work was supported by the National Natural Science Foundation of China (No. 81520108010 and 81771216) and the Primary Research and Development Plan of Zhejiang Province (No. 2020C03020).

Supporting information
======================

###### 

Data S1

###### 

Click here for additional data file.

###### 

Data S2

###### 

Click here for additional data file.

###### 

Data S3

###### 

Click here for additional data file.

We would like to express our gratitude to all the patients and their families who participated in this study.
